The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Interpreting the clinical significance of the differential inhibition of cyclooxygenase-1 and cyclooxygenase-2
Abstract
The International Consensus Meeting on the Mode of Action of COX-2 Inhibition (ICMMAC) brought together 17 international experts in arthritis, gastroenterology and pharmacology on 5 6 December 1997. The meeting was convened to provide a definition of COX-2 specificity and to consider the clinical relevance of COX-2-specific agents. These compounds are a new class of drugs that specifically inhibit the enzyme COX-2 while having no effect on COX-1 across the whole therapeutic dose range. The objectives of the meeting were to review the currently available data regarding the roles and biology of COX-1 and COX-2, and to foster a consensus definition on COX-2 specificity. At the present time, no guidelines exist for the in vitro and in vivo assessment of COX specificity, and it was felt that consensus discussion might clarify some of these issues. The meeting also reviewed recent clinical data on COX-2-specific inhibitors. The following article reflects discussion at this meeting and provides a consensus definition of COX-2-specific inhibitors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Selective inhibition of inducible cyclooxygenase 2 in vivo is antiinflammatory and nonulcerogenic.
Masferrer, J. L., Zweifel, B. S., Manning, P. T., Hauser, S. D., Leahy, K. M., Smith, W. G., Isakson, P. C., & Seibert, K. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.8.3228 · Cited by 1,310
Cited by
Hawkey, C. (1999) · The Lancet · doi:10.1016/s0140-6736(98)12154-2 · Cited by 1,173
Self-citationIbuprofen: pharmacology, efficacy and safety
Rainsford, K. D. (2009) · Inflammopharmacology · doi:10.1007/s10787-009-0016-x · Cited by 667
Lanas, A., García-Rodríguez, L. A., Arroyo, M. T., Gomollón, F., Feu, F., González-Pérez, A., Zapata, E., Bástida, G., Rodrigo, L., Santolaria, S., et al. (2006) · Gut · doi:10.1136/gut.2005.080754 · Cited by 524
Riendeau, D., Percival, M. D., Brideau, C., Charleson, S., Dubé, D., Ethier, D., Falgueyret, J.-P., Friesen, R. W., Gordon, R., Greig, G., et al. (2001) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)38776-2 · Cited by 460
The development of COX2 inhibitors
Flower, R. J. (2003) · Nature Reviews Drug Discovery · doi:10.1038/nrd1034 · Cited by 459
Metadata
- Authors
- Brooks, P., Emery, P., Evans, J. F., Fenner, H., Hawkey, C. J., Patrono, C., Smolen, J., Breedveld, F., Day, R., Dougados, M., Ehrich, E. W., Gijon-Baños, J., Kvien, T. K., Van Rijswijk, M. H., Warner, T., & Zeidler, H.
- Venue
- Rheumatology
- Publisher
- Oxford University Press (OUP)
- Published
- 1999-08
- Volume
- 38
- Issue
- 8
- Pages
- 779-788
- ISSN
- 1462-0324 (ISSN-L)
- 1462-0332
- OpenAlex
- W2164397284
- Cited by
- 222
- References
- 1
- FWCI
- 12.92
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Interpreting the clinical significance of the differential inhibition of cyclooxygenase-1 and cyclooxygenase-2. https://app.cochat.ai/papers/10.1093/rheumatology/38.8.779
- The paper
- Brooks, P., Emery, P., Evans, J. F., Fenner, H., Hawkey, C. J., Patrono, C., Smolen, J., Breedveld, F., Day, R., Dougados, M., Ehrich, E. W., Gijon-Baños, J., Kvien, T. K., Van Rijswijk, M. H., Warner, T., & Zeidler, H. (1999). Interpreting the clinical significance of the differential inhibition of cyclooxygenase-1 and cyclooxygenase-2. Rheumatology. https://doi.org/10.1093/rheumatology/38.8.779
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.